Poliprotect in the PPI Deprescription Phase of Endoscopy‐Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis
Neurogastroenterology & Motility · 2026-06 · 38 (6)
DOI: 10.1111/nmo.70370 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 01.06.2026. Verfasst von Enrico Stefano Corazziari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centro di Eccellenza in Malattie Gastroenterologiche, Ospedale Isola Tiberina, Rome, Italy. Hauptthemen laut MEDLINE: Abdominal Pain, Deprescriptions, Heartburn, Proton Pump Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) are widely used for upper gastrointestinal symptoms but are frequently prescribed inappropriately and often continued without clear indications. Deprescribing PPIs can be challenging due to symptom recurrence or rebound acid hypersecretion. The mucosal protective agent Poliprotect, a natural formulation with barrier, antioxidant, and anti‐inflammatory properties, has shown non‐inferiority to omeprazole in non‐erosive heartburn and epigastric pain syndrome (EPS) without affecting intestinal microbiota.
Aim
To evaluate the role of Poliprotect formulation (neoBianacid) in maintaining symptom control after PPI withdrawal in patients with endoscopy‐negative heartburn (HRTB) and EPS.
Methods
This post hoc analysis used data from a multicenter, double‐blind RCT including 125 endoscopy‐negative patients (80 with HRTB, 45 with EPS) treated with omeprazole 20 mg/day for 4 weeks, followed by 4 weeks of on‐demand Poliprotect after PPI discontinuation. Outcomes included symptom severity (VAS), responder rate (≥ 50% VAS reduction), use of rescue medication, quality of life (GIQLI), gastrointestinal symptoms (GSRS), treatment satisfaction, and safety.
Results
At the end of deprescription, mean VAS scores remained stable, and 69.5% of PPI responders (65.8%, HRTB, and 76.2%, EPS) maintained symptom control. Additionally, 31% of PPI non‐responders (33.3%, HRTB, and 27.3%, EPS) became responders with Poliprotect. Rescue antacid use and quality of life scores were not significantly changed. No adverse events were reported during the deprescribing phase.
Conclusions
On‐demand Poliprotect was associated with maintenance of symptom control after PPI withdrawal and outcome improvement in approximately one‐third of PPI non‐responders. Poliprotect appears to be a safe, well‐tolerated, and promising strategy to support PPI discontinuation in endoscopy‐negative heartburn and EPS patients. Trial Registration Clinicaltrial.gov (NCT03238534) and EudraCT Database (2015–005216‐15)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro di Eccellenza in Malattie Gastroenterologiche, Ospedale Isola Tiberina, Rome, Italy.
- Medicina Interna e Gastroenterologia, CEMAD Centro Malattie Dell'apparato Digerente, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Azienda Opedaliera S.Camillo-Forlanini, Rome, Italy.
- Unit of Gastroenterology and Digestive Endoscopy, S.Eugenio Hospital, Rome, Italy.
- Dipartimento di Medicina Translazionale e di Precisione, Sapienza University of Rome, Rome, Italy.
- Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
ORCID-Profile: Enrico Stefano Corazziari, Valeria D'Ovidio, Carolina Ciacci, Emanuela Ribichini, Paola Iovino
Zitieren
APA
Corazziari, E. S., Gasbarrini, A., D'Alba, L., D'Ovidio, V., Riggio, O., Passaretti, S., Annibale, B., Cicala, M., Repici, A., Bassotti, G., Ciacci, C., Di Sabatino, A., Neri, M., Bragazzi, M. C., Ribichini, E., Iovino, P., & Badiali, D. (2026). Poliprotect in the PPI Deprescription Phase of Endoscopy‐Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis. Neurogastroenterology & Motility, 38(6). https://doi.org/10.1111/nmo.70370
Vancouver
Corazziari ES, Gasbarrini A, D'Alba L, D'Ovidio V, Riggio O, Passaretti S, et al. Poliprotect in the PPI Deprescription Phase of Endoscopy‐Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis. Neurogastroenterology & Motility. 2026;38(6). doi:10.1111/nmo.70370
BibTeX
@article{Corazziari2026,
author = {Corazziari, Enrico Stefano and Gasbarrini, Antonio and D'Alba, Lucia and D'Ovidio, Valeria and Riggio, Oliviero and Passaretti, Sandro and Annibale, Bruno and Cicala, Michele and Repici, Alessandro and Bassotti, Gabrio and Ciacci, Carolina and Di Sabatino, Antonio and Neri, Matteo and Bragazzi, Maria Consiglia and Ribichini, Emanuela and Iovino, Paola and Badiali, Danilo},
title = {Poliprotect in the PPI Deprescription Phase of Endoscopy‐Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis},
journal = {Neurogastroenterology & Motility},
year = {2026},
volume = {38},
number = {6},
doi = {10.1111/nmo.70370}
}
EUVIMED